Alector

Today, we announced topline results from the Phase 3 INFRONT-3 trial evaluating an investigational progranulin-elevating therapy in individuals with frontotemporal dementia due to a GRN mutation. Read more: http://bit.ly/3KUcAkJ

#DYK, there are several different types of dementia, and they each affect the brain and patients in profoundly different ways? Understanding the differences, signs & symptoms, and path for diagnosis are all critical to improving awareness and care.    Swipe to learn more.   #DementiaAwareness #BrainHealth

Alector’s patient advocacy team joined the Alzheimer's Foundation of America Educating America Tour in Charleston, West Virginia this month. We’re proud to support this important initiative, which brings education, resources, and support nationwide to the Alzheimer’s community. Many thanks to the AFA team for your inspiring dedication!

On this #MentalHealthAwarenessDay, let us consider the importance of destigmatizing mental illness, supporting one another, and making mental health a priority in our communities. Today – remember to check in with yourself, take a deep breath, and slow down. Everyone deserves a hopeful future – you are not alone! 

Last week, in honor of #FTDAwarenessWeek, Alector invited Dr. Jary Larsen, neuropsychologist at the University of California, San Francisco, who shared his expertise and insights during a discussion about #FTD-GRN.   As part of the week, the team also wore red in solidarity with the FTD community, reflecting on the importance of advancing research and support for people living with frontotemporal degeneration and their families.   We are grateful to Dr. Larsen for joining us and to our team for coming together during this important week!

October is #HealthLiteracyAwareness month, and at Alector we believe that breakthrough science needs to be paired with efforts to support disease education for informed health decisions. We are proud to support advocacy groups including The Association for Frontotemporal Degeneration (AFTD), CureGRN, For Their Thoughts Foundation, Genetic ALS & FTD: End the Legacy, Cure MAPT FTD, and Lorenzo's House whose tireless efforts raise awareness and bring hope to families impacted by neurodegenerative disease.

Meet David Moore, Clinical Trial Manager at Alector. David’s favorite part of his role is collaborating with an incredible team that consistently shows up ready to tackle each day’s challenges. Outside of work, he enjoys fishing, golfing, and hunting. Learn more about David below!

Our Patient Advocacy team joined the Alzheimer's Foundation of America at their next Educating America tour stop in Omaha! We’re proud to be a part of this important community, and are grateful for their continued dedication to the #Alzheimer’s community.

This #FTDAwarenessWeek, we recognize the dedicated caregivers who provide essential support to those living with dementia — work that is vital and incredibly hard. At Alector, we are also grateful for the incredible patient advocacy groups we partner with, including The Association for Frontotemporal Degeneration (AFTD), Genetic ALS & FTD: End the Legacy, For Their Thoughts Foundation, The Bluefield Project to Cure Frontotemporal Dementia, Lorenzo's House, CureGRN, & Cure MAPT FTD. Your commitment makes a lasting impact for patients and their loved ones.

On this #AlzheimersAwarenessDay, we reaffirm our commitment to a world where neurodegeneration no longer steals memories, independence, or connection. Every step in our journey — from discovery to development — is driven by the courage of patients, the dedication of caregivers, and the resilience of communities navigating Alzheimer’s disease. To those living with Alzheimer’s, their loved ones, and caretakers: we see you and we’re working every day to make a difference. Learn more about our mission: http://bit.ly/3IA6AfQ